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Over the past decade, major discoveries in retrotransposon biology have
depicted the neural genome as a dynamic structure during life. In particular,
the retrotransposon LINE-1 (L1) has been shown to be transcribed and mobi-
lized in the brain. Retrotransposition in the developing brain, as well as
during adult neurogenesis, provides a milieu in which neural diversity
can arise. Dysregulation of retrotransposon activity may also contribute to
neurological disease. Here, we review recent reports of retrotransposon
activity in the brain, and discuss the temporal nature of retrotransposition
and its regulation in neural cells in response to stimuli. We also put forward
hypotheses regarding the significance of retrotransposons for brain develop-
ment and neurological function, and consider the potential implications of
this phenomenon for neuropsychiatric and neurodegenerative conditions.1. Introduction
The mammalian brain is remarkably complex in form and function. Neural cell
diversity underpins this complexity, and has classically been defined in terms
of the morphological differences between cell types, their diverse connectivity
patterns, physiological and functional properties and the expression of various
transcription factors (TFs), cell surface and secreted molecules [1,2]. At the same
time, it has been assumed that the neural cells of any individual will all carry
the same genetic instructions, or genotype, and that cellular diversity is
achieved by changing how these instructions are read, for example, through
epigenetic modifications [3]. However, recent advances in DNA sequencing
and genetic analysis, as well as bioinformatics, have made it possible to identify
mutations generating distinct genotypes among the neurons of an individual
human brain. These mutations include single-nucleotide variants, copy
number variants (CNVs) and retrotransposon insertions [4–10]. Collectively,
these genetic variants form a landscape of somatic mosaicism within the brain.
Somatic mosaicism is defined as the existence of two or more cells with
different genotypes within one individual. Depending on its developmental
timing, mosaicism can encompass mutations that are heritable (germline mosai-
cism), non-heritable (somatic mosaicism) or a combination of these two
outcomes [9,11–14]. Retrotransposons, colloquially referred to as ‘jumping
genes’, are DNA fragments that have the ability to copy their sequences from
one location in the genome and insert themselves into a new genomic position,
causing mutations and changing the genomic landscape at the new integration
site. It is now established that retrotransposons are endogenous mediators of
somatic mosaicism in the brain [4–7,10,14]. As remnants of mammalian
genome evolution, retrotransposons may occupy up to two-thirds of the
human genome [15], but most human retrotransposon copies have lost their
ability to mobilize further [16]. However, some elements are still capable of
mobilization, in the germline and in the soma. Over the past decade, several
studies have shown that retrotransposons contribute to intra-individual vari-
ation in neuronal genomes, defining a new layer of neural diversity and
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may be essential for healthy brain function, while its disrup-
tion may play a role in neurological diseases [17,18]. To
provide a comprehensive understanding of the roles retro-
transposons play in neural function, and their potential
contribution to disease, we will first present an overview of
the active retrotransposon families in humans, their mobiliz-
ation mechanism, and experimental strategies for studying
neuronal retrotransposition. g.org
Open
Biol.8:1800742. Types of retrotransposons in the human
genome
Retrotransposons are the main class of transposable elements
found in most mammalian genomes. Based on the presence
of long terminal repeats (LTR) in their structure, they are
classified into LTR and non-LTR retrotransposons. The LTR
group consists of ERVs (endogenous retroviruses), which
comprise approximately 8% of the human genome and rep-
resent remnant retrovirus sequences incorporated into the
host germline after ancient viral infections [19,20]. The non-
LTR retrotransposon group is further subdivided based on
the ability of elements to mobilize independently or only
with the machinery encoded by another retrotransposon,
into autonomous and non-autonomous elements, respect-
ively. Long interspersed element 1 (LINE-1 or L1) is the
only autonomous non-LTR retrotransposon in humans. In
addition to its own mobilization in cis, L1 can mobilize in
trans non-autonomous short interspersed element (SINE) ret-
rotransposons. These include 7SL-derived Alu elements,
composite SVA (SINE–variable number tandem repeat–
Alu) elements, and cellular mRNAs, resulting in processed
pseudogenes [21–25]. L1 copies can be over 6 kb in length
and occupy the highest proportion of the human genome
by sequence of all the transposable elements (approx. 17%)
[19]. Alu copies are approximately 300 bp in size and rep-
resent the most abundant transposable element by copy
number (approx. 11% by sequence) [19,26,27]. SVAs are
approximately 2 kb in size, with far fewer copies than L1 or
Alu, and comprise only about 0.2% of the genome sequence
[19,28–30] (figure 1a).
Owing to truncation, deletion, internal rearrangement
and other mutations, the vast majority of human retrotran-
sposon sequences are incapable of further mobilization and
are considered molecular fossils [16]. Computational-,
molecular- and genomics-based studies have to date identified
and catalogued retrotransposons into evolutionary families
and subfamilies. Only a few L1, Alu and SVA subfamilies
remain mobile. Moreover, functional studies have identified
that most retrotransposition-competent L1s are part of a
small group of elements termed Ta (transcribed-active) L1s
[38]. All of the L1s reported to be highly active in vitro to
date belong to the L1-Ta and L1-preTa families [39–42]. Simi-
larly, particular Alu subfamilies, such as AluYa5 and AluYb8
[43], and SVA E, F and F1 subfamilies [19,24,29] have been
identified as the most active in humans. Human ERVs
(HERVs) are considered to be immobile in modern humans,
although a recent study revealed several polymorphic
HERV-K insertions in the global population and a full-
length, intact, insertion with potentially functional open
reading frames (ORFs) [44]. However, it remains unclearwhether this insertion is a recently integrated provirus or has
simply been lost in some individuals.3. An overview of the retrotransposon
mobilization mechanism
All retrotransposons mobilize via a replication mechanism
involving an RNA intermediate [45]. During this process,
termed retrotransposition, the host polymerase starts the syn-
thesis of an RNA copy of the element and, subsequently, the
RNA is reverse transcribed into DNA by an element-encoded
reverse transcriptase. HERV reverse transcription takes place
in the cytoplasm and the viral DNA is then transported into
the nucleus and integrated into a viral integrase which cata-
lyses insertion of the HERV into its new target site [46]. L1
produces a bicistronic mRNA that is transported to the cyto-
plasm and translated. L1 encodes proteins that present a
strong cis-preference [47], meaning they tend to bind to
their encoding mRNA. This results in the formation of
ribonucleoprotein particles (RNPs) that may localize to cyto-
plasmic stress granules [48,49] or enter the nucleus. In the
case of L1, reverse transcription occurs in the nucleus,
where the L1-encoded endonuclease [33] makes a single-
strand cleavage at the target DNA, exposing a 3’ hydroxyl
group, which is used as a primer for reverse transcription
by the L1-encoded reverse transcriptase [34] (termed target-
primed reverse transcription, or TPRT) [36,37]. TPRT
typically results in L1 insertions with the following sequence
features: insertion at an L1 endonuclease motif (5’-TTTT/
AA), target site duplications (TSDs) and a poly(A) tail
(figure 1b) [33,50,51].
Retrotransposition does not always result in the faithful
duplication of an element, particularly in the case of L1.
Owing to errors during reverse transcription, only approxi-
mately 40% of L1 copies are identical to their source, or
donor, L1 [52]. Also, 5’ truncation, which is a common
characteristic of recent human L1 insertions [19,53], may
occur, likely because of the premature dissociation of the
reverse transcriptase from the L1 mRNA strand during
TPRT. The precise mechanism through which 5’ truncation
occurs is not clearly understood, although it has been specu-
lated that DNA repair may play a role as host DNA repair
factors, such as ATM (ataxia telangiectasia mutated), may
limit the size of L1 insertions [54].
As a result of 5’ truncations, internal inversions or del-
etions [55] and point mutations, only about 80–100 [41,42]
L1 copies are estimated to be able to retrotranspose per aver-
age human genome, with even fewer copies accounting for
most new L1 insertions [41,56–58]. One new L1 insertion is
generated per 100–200 human births [42,59]. By contrast,
3000 L1 copies [60] are estimated to be retrotransposition-
competent in the mouse genome, with at least one in eight
mice harbouring a new L1 insertion [11].4. Detection of retrotransposon activity in
the healthy brain
Although nearly 70 years have passed since Barbara McClin-
tock’s seminal studies of transposable elements in maize
[61,62], ongoing L1 retrotransposition in modern human gen-
omes was only demonstrated in 1988 [63]. Subsequently,
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Figure 1. (Caption opposite.)
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embryonic development, germ cells and various diseases,
such as cancer [63–69]. Insertions arising during early devel-
opment or in cancer cells are likely to undergo clonal
expansion, resulting in a significant proportion of cells har-
bouring a particular insertion. Studying the contribution of
L1 insertions to somatic mosaicism in normal tissues,however, presents a particular technical challenge, as these
genomic variants may be found only in a limited number
of cells.
Over the past decade, three main tools have facilitated the
discovery and study of L1 retrotransposition in the brain.
Firstly, an engineered L1 reporter construct, previously devel-
oped to recapitulate L1 retrotransposition in cultured cells
Figure 1. (Opposite.) Human retrotransposon families and mobilization mechanism. (a) Types of retrotransposons, their mobilization capacity, size and number of
copies in the human genome. HERV, human endogenous retroviruses consisting of two LTRs; gag, group-specific antigen; pol, polymerase; env, envelope gene; long
interspersed element-1 (L1) structure: 50 untranslated region (UTR) with open reading frame (ORF)0 and promoter activity; ORF1 and ORF2; 30 UTR and poly(A) tail;
SVA structure: CCCTCT hexamer repeats (HR), Alu sequence in reverse orientation (Alu-like); VNTR, variable number of tandem repeats; SINE-R, a short interspersed
element of HERV origin; An, poly(A) tail; Alu structure: a left monomer with internal RNA polymerase III promoter binding sites (A, B boxes); AAA, adenosine-rich
linker; right monomer ending in poly(A) tail (An); processed pseudogene: sequence derived from cellular messenger RNA, which has been reverse transcribed into
DNA and has no introns; target side duplications are shown as white triangles. (b) L1 retrotransposition mechanism as an example of retrotransposon mobilization. A
full-length, retrotransposition-competent L1 is present at one genomic locus (blue box in the left grey chromosome). The L1 encodes two proteins essential for its
mobility, ORF1p (with nucleic acid chaperone activity [31,32]) and ORF2p (with endonuclease [33] and reverse transcriptase [34] activity), as well as an unusual
antisense ORF0 that may facilitate retrotransposition [35]. L1 transcription results in a bicistronic, polyadenylated mRNA (blue rectangle), which is transported to the
cytoplasm for translation. Upon translation, ORF1p and ORF2p (blue spheres) bind to their encoding L1 mRNA in cis and form an RNP complex. Note that the L1
proteins can retrotranspose cellular mRNAs to generate processed pseudogenes, as well as SVA and Alu retrotransposons (purple, red and yellow wavy lines). Once
the RNP is formed, it enters the nucleus through a still poorly understood process, where a new L1 insertion occurs by target-site primed reverse transcription (TPRT)
[36,37]. During TPRT, the ORF2p endonuclease makes a first and second cleavage (red arrows) in the genomic DNA at the consensus sequence 5’-TTTT/AA [33], and
releases a 3’ hydroxyl (OH) group from which the ORF2p reverse transcriptase initiates reverse transcription of the attached L1 mRNA (indicated by the red dashed
line arrow). The DNA fragment between the two cleavages is highlighted in green to indicate the formation of TSDs. The black dashed arrow indicates completing
synthesis across the second strand of cDNA, resulting in a new L1 copy, and the TSDs, which flank the new L1 copy.
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sposition in human embryonic stem cell (hESC)-derived
neural progenitor cells (NPCs), rodent NPC cultures and
transgenic animal models [71]. The L1 construct consists of
a human L1 sequence and a gene encoding enhanced green
fluorescent protein (EGFP) in reverse orientation to the L1
transcript. The EGFP gene is interrupted by an intron in the
same transcriptional orientation as the L1. Thus, only cells
with successful L1 retrotransposition events can express
GFP because the EGFP intron is removed from the RNA
intermediate, followed by reverse transcription and inte-
gration into a genomic location. When the L1-EGFP system
is employed in neuronal cultures, GFP co-localizes with neur-
onal markers Map2 and b-tubulin, whereas very little to no
GFP co-localizes with astrocyte or oligodendrocyte markers
[72]. Neurons obtained from transgenic L1-EGFP mouse
brain sections were positive for GFP expression, in a variety
of different brain areas, such as cortex, hypothalamus,
amygdala and hippocampus [72–74]. Although the genomic
location of the engineered L1 transgene may result in
unknown epigenetic effects that do not necessarily recapitu-
late the regulation of endogenous L1 copies, this type of
assay remains a valid tool to understand the effects of L1
and other retrotransposon activity on neural cell function.
With recent advances in genome editing technology [75],
the design of site-targeted reporter constructs, as well as con-
ditional inducible constructs for temporal and cell-specificity,
is more easily achievable and may be instrumental in
dissecting the parameters of retrotransposition in the brain.
Secondly, to estimate the number of L1 copies across
different tissues and brain areas, Coufal et al. [76] developed
a TaqMan quantitative PCR-based L1 CNV assay. This assay
estimated an enrichment of L1 copies in the human brain
when compared with other tissues, with more L1 copies
also found in the hippocampal dentate gyrus than in other
brain areas [4,74,76]. The authors [76] estimated 80 somatic
L1 insertions occurred per neuron. Owing to the high copy
numbers of L1 sequences already present in the genome
[19], this assay offers very limited sensitivity when attempt-
ing to quantify variation in the number of L1 insertions in
somatic tissues. Moreover, the assay does not discriminate
integrated copies generated by TPRT from potential extra-
chromosomal L1 DNAs or any other source of L1 CNV notarising from retrotransposition [77]. New quantitative PCR
approaches, such as digital droplet PCR (ddPCR), may
prove a better tool to quantify retrotransposon CNV in a
more accurate but still cost-effective manner [78,79].
Thirdly, high-throughput DNA sequencing strategies
have been developed to detect, quantify and resolve L1
insertions. Whole-genome sequencing (WGS) or targeted
sequencing of retrotransposon–genome junctions has been
applied to bulk brain, pooled neurons and whole-genome
amplified (WGA) material from single neuronal nuclei
from post-mortem human brain [4–7,10,80]. Tissues from
other parts of the body, such as liver or blood, have been
used to discriminate somatic and polymorphic insertions
(i.e. insertions found in neurons and absent in non-brain
tissue are annotated as somatic). Databases of known retro-
transposon insertion polymorphisms can also be used to
discriminate novel and known insertions. To fully charac-
terize most new insertions, thorough PCR validation
followed by Sanger sequencing is required [81,82]. One of
the advantages of using high-throughput DNA sequencing
is that it allows not only for detection and quantification of
endogenous L1 variants, but also for resolving the structure
and genomic location of these insertions. Resolving
the structure of a specific insertion is paramount in under-
standing the potential functional impact of the insertion on
the genome.
Providing a valuable orthogonal approach to single-cell
genomic analysis, a recent study used somatic cell nuclear
transfer to reprogramme postmitotic olfactory bulb neur-
ons into enucleated oocytes and cloned the neuronal
genome to produce enough DNA for WGS without the
need for WGA. WGS analysis of the resulting clones
revealed several de novo L1 insertions [14]. These studies
altogether demonstrate that L1-driven somatic mosaicism
can occur in the mammalian brain. However, with
single-cell genomic analysis in its infancy, methodological
variation, including the use of different cell populations as
starting material, has led to estimates ranging from one
L1 insertion per 25 neurons [5] to 13.7 L1 insertions per
neuron [10]. Therefore, although these studies offer
strong evidence of L1 retrotransposition in the brain, the
frequency of retrotransposition in neural cells requires
further investigation [83].
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Figure 2. Timeline of retrotransposition activity in the brain. (a) Retrotransposition can occur in the germline, during embryogenesis, as well as during nervous
system development, and can involve neural stem cells (NSCs), NPCs and post-mitotic neurons. Retrotransposition events could accumulate over time and also,
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retrotransposition in the brain?
Retrotransposition in the brain could occur at any stage of
life, from early brain development to brain maintenance
and decline during adulthood, and also influence neural
diversity and survival (figure 2a). Neural diversity arises
during early embryogenesis through the spatial and temporal
patterning of neuroblasts and neuronal progenitor cells.
A complex network of gene expression determines a particular
cell type-specific progenitor domain and fate [84]. Expression
of pan-neuronal genes marks the beginning of neurogenesis
and specific TFs are required for neuronal differentiation.Differentiating neurons migrate, grow axonal processes and
later form synapses. Various signalling molecules, TFs and
cell receptor molecules tightly control this development [85].
Although the bulk of neurons are generated during embryonic
neurogenesis, neurons are also born in specific areas of the
postnatal brain, such as hippocampus, olfactory system and
amygdala [86,87]. An estimated 700 neurons are renewed in
the human hippocampus daily [88]. Whether retrotransposi-
tion occurs during adult neurogenesis, or during embryonic
development, in neuroblasts, committed neural progenitors,
or in mature neural cells, determines the number of somatic
L1 insertions harboured by a given cell. The spatio-temporal
parameters of somatic L1 retrotransposition therefore will
rsob.roy
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ticular insertion and, most importantly, will govern the overall
impact an individual insertion may have on brain activity
(figure 2b).alsocietypublishing.org
Open
Biol.8:1800745.1. Retrotransposition in embryonic and adult
neurogenesis
Over a decade ago, Muotri et al. [72] presented the first evi-
dence that L1 retrotransposons can mobilize during
neuronal differentiation. Using a human L1-EGFP reporter
system, L1 expression was observed both in vitro, in rodent
primary hippocampus-derived NPC cultures, and in vivo, in
transgenic mice. L1 expression in transgenic mice was
observed as early as embryonic day (E) 12.5, when the first
waves of immature differentiated neurons appear in the
brain [72]. These data were later corroborated and advanced
by Coufal et al. [76] in a study reporting L1 reporter activity
and endogenous L1 mRNA expression in human NPCs
either isolated from fetal brain or derived from hESCs. The
preference of retrotransposition for proliferating progenitor
cells may be related to the cell cycle. Several studies reported
an elevated rate of L1 retrotransposition in dividing cells
which suggests that, although non-dividing cells can accom-
modate L1 retrotransposition [12,89], the cell cycle may
promote efficient retrotransposition [90–92]. The mechanism
through which the L1 RNP enters the nucleus is not well
understood. However, live-cell imaging experiments tracking
an L1 reporter construct during cell cycle progression indicate
that L1 enters the nucleus as the cell starts to divide, presum-
ably facilitated by nuclear envelope disassembly during
mitosis [92].
Another explanation for L1 activity in proliferating NPCs
may be a more relaxed chromatin state. A relaxed chromatin
state is correlated with pluripotency and proliferation, and
differentiated cells have more condensed chromatin than pro-
genitor cells [93]. Open chromatin has been assumed to
facilitate L1 activation. By using a transcription activator-
like (TAL) effector to target different parts of a mouse L1,
which was then fused with a transcriptional activator
domain, a recent study demonstrated that L1 transcription
directly impacts global chromatin accessibility in the early
mouse embryo [94]. L1 transcriptional activity to maintain
chromatin openness may be a prerequisite for normal devel-
opment of the early embryo [94] and it will be interesting to
further extend this study into later developmental stages and
in the context of neurodevelopment.
Finally, TFs can stimulate L1 to retrotranspose during
neuronal differentiation. Sex determining region Y-box 2
(SOX2), which is expressed in stem cells and neural progeni-
tors, and is essential in maintaining a proliferative state, can
bind to the 5’ UTR of L1 and repress promoter activity [72].
During neuronal differentiation, when SOX2 is downregu-
lated, L1 can become active [72]. Concomitantly, members
of the Wnt signalling pathway such as wingless-related inte-
gration site family member 3a (WNT3a), which promotes
neurogenesis, can also stimulate and increase L1 trans-
cription, providing a window of opportunity for L1
mobilization to occur in differentiating neurons [73]. Hence,
the shifting epigenetic and transcriptional landscapes of neu-
rogenesis may provide a unique situation for somatic
retrotransposition to occur in the brain.5.2. Retrotransposition in postmitotic neurons
If we accept that endogenous L1 mobilization can occur
during adult neurogenesis, can it also occur in postmitotic
neurons? This is a fundamental question because the lifespan
of mature neurons can be as long as a human lifespan, and
therefore, any potential for somatic retrotransposition in
this context may lead to the largest absolute accumulation
of new L1 insertions found in the brain. Crucially, Kubo
et al. [89] showed in 2006 that engineered L1 retrotransposi-
tion can occur in non-dividing human fibroblasts and
hepatocytes and, much more recently, Macia et al. [12] con-
firmed that this was also true for postmitotic neurons.
Macia et al. compared the retrotransposition of a hybrid ade-
noviral L1-EGFP vector in dividing versus non-dividing
neural cells by infecting NPC cultures with the L1 reporter
and concomitantly adding 5’-bromo-2’-deoxyuridine
(BrdU), which labels dividing cells. Immunostainings of dif-
ferentiated NPC cultures infected with L1-EGFP at 31 days
post-NPC differentiation showed the presence of neurons
expressing only EGFP but not the cycling marker, BrdU.
When comparing the number of integrated L1-EGFP copies
in cultures infected with the L1 reporter at day 0 (multi-
potent NPC) versus day 31 of differentiation (in mature
neurons), a sixfold increase in L1-EGFP copies was observed
by qPCR against the EGFP splice junction in mature neurons,
even when correcting for differences in proliferation rate [12].
This was an astonishing result, as it supports speculation that
not only do mature neurons support retrotransposition, but
also retrotransposition occurs at even higher rates in neurons
than in proliferating neural progenitors. The study relied
heavily on qPCR detection of EGFP copies, and used an
in vitro assay to compare dividing versus non-dividing
neural cells. Going forward, it will be interesting to address
this question in vivo, perhaps by using an inducible knock-
in reporter model. Furthermore, it would be very interesting
to explore in detail the mechanisms through which retro-
transposons escape epigenetic silencing and mobilize in
postmitotic neurons.6. Is retrotransposition necessary for
healthy brain function?
It is not established whether retrotransposition in the neural
genome is part of normal brain function. It is however plaus-
ible that, if retrotransposons did contribute to normal brain
function, it would be via altered splicing and DNA methyl-
ation of genes, with these being routes to perturb the
transcriptional output of cells. For example, pseudogene tran-
scripts can carry microRNA (miRNA) recognition sites and
facilitate degradation of their target miRNAs, acting as com-
petitive miRNA targets to the miRNA targets of their parent
genes [95]. Such pseudogenes carrying miRNA recognition
sites are present in temporal lobe neurons, where they may
play an important role in regulating the expression of
miRNAs [96]. Somatic pseudogene insertions in the brain, if
found, may therefore regulate gene regulation as miRNA
‘sponges’ [97]. In another example, experiments using L1-
EGFP transgenic rodents, which were either sedentary or
allowed to voluntarily run, demonstrated that exercise
increased the total number of newborn hippocampal neur-
ons, which correlated with an increase in engineered L1
rsob.royalsocietypublishing.org
Op
7
 on July 30, 2018http://rsob.royalsocietypublishing.org/Downloaded from retrotransposition [98]. However, it remains unclear whether
the increase in GFP was due to a greater number of insertions
in the running mice or an activation of GFP expression from
previously silenced L1-EGFP insertions, due to changes in the
epigenetic landscape. Nevertheless, as the hippocampus is an
important area for brain structural plasticity, being involved
in learning, memory as well as stress regulation, retrotranspo-
sition in hippocampal neurons could potentially contribute to
neuronal plasticity. Whether retrotransposon insertions can
actively contribute to neuronal physiology, and thus impact
behaviour, is still debatable, as to date no functional analyses
have been published in this area.en
Biol.8:1800747. Retrotransposition-induced genomic
alterations in neuronal genes and their
functional consequences
Retrotransposon insertions can significantly alter protein-
coding and regulatory regions of the genome, and thereby
affect gene expression and other cellular outputs [63,68,99–
103]. L1 insertions can occur within neuronal genes, and
therefore have the potential to change the structure of genes
or how highly they are expressed [4,7,10,72,99]. The conse-
quences of an intragenic L1 insertion for a cell depend on: (i)
the characteristics of the insertion (full-length or 5’ truncated
L1, sense or antisense to the gene; internally inverted and
deleted); (ii) the locus where it integrates; and (iii) the ability
of the host cell to silence or compensate for the effects of the
L1 insertion [104,105]. The various routes by which L1 inser-
tions can lead to gene expression changes have been
reviewed previously [106–108]. L1 insertions can delete
sequences at the target site [52,109]. In some cases, these del-
etions can be quite large, such as the 46 kb deletion reported
for the PDHX gene encoding pyruvate dehydrogenase,
which results in pyruvate dehydrogenase deficiency, a neuro-
degenerative disorder [110]. Genomic sequences flanking the
source L1 5’ or 3’ end can be transduced along with the L1
to the new integration site, potentially leading to exon
shuffling and new genes [111]. Recombination can occur
between retrotransposons, causing deletions, duplications or
rearrangements in genes [112]. Transcriptional stop sites and
polyadenylation signals can be introduced by new retrotran-
sposon sequences, leading to premature transcriptional
termination [99,113]. An antisense promoter located in the L1
5’ UTR can also create new transcription start sites for genes
upstream of the L1 [35,114–116], meaning that both intragenic
and intergenic L1 insertions may alter gene expression.
New L1 insertions can lead to aberrant transcriptional spli-
cing [117–121]. Two prominent examples of this are provided
by mice bearing spontaneous mutations with neurological
phenotypes: the Spastic and Orleans reeler mice. Firstly, the
Spastic mouse harbours a germline full-length L1 insertion
into a non-coding region of the glycine neurotransmitter recep-
tor b (Glyrb) gene which leads to aberrant splicing of the
pre-mRNA by exon skipping, thus resulting in reduced intact
subunit b expression in the brain [118,119]. As the b subunit
is required for glycine receptor protein assembly, this insertion
leads to a decrease in glycine receptors in the brain and a com-
plex motor deficit phenotype. Secondly, the Orleans reeler
mouse incorporates a full-length L1 insertion into a coding
region of the Reelin (Reln) gene, which also leads to exonskipping and a frame shift, in this case generating a 220 bp del-
etion of the Reln mRNA, and leading to inefficient secretion of
Reln truncated protein [120,122,123]. As Reln is essential for
neuronal migration and cortical lamination, deficiency in its
secretion leads to a severe impairment of neuronal migration
and, as a consequence, cortical and cerebellar delamination.
Subsequent neurological symptoms in Reln mutant mice reca-
pitulate the phenotype seen in patients with lissencephaly
caused by other Relnmutations [124]. Hence, de novo L1 inser-
tions arising in the germline can alter genes expressed in the
brain and cause a neurological phenotype, suggesting that
similar mutations arising in neurons have the potential to
generate a functional change.8. Retrotransposon regulation and
environmental factors impacting
retrotransposition
8.1. Locus-specific regulation of long interspersed
element 1 retrotransposition
Retrotransposition depends on a mobile element’s intrinsic
ability to ‘jump’, and its host cell’s capacity to defeat this
mobilization. Despite their significant presence in the
genome, almost all human L1 copies are 5’ truncated, or con-
tain internal mutations and rearrangements, and are not able
to mobilize. A few L1 copies are full length, remain transcrip-
tionally active and have intact ORFs and therefore have the
capacity to act as source, or donor, elements in a cycle of retro-
transposition. An even smaller subset (approx. 6 L1s per
individual genome) retrotranspose efficiently in vitro when
tagged with a fluorescent or selectable marker [50,70] and are
referred to as ‘hot’ donor L1s [41,42], although retrotransposi-
tion efficiency can vary significantly in different cell types. Hot
L1s tend to be the most recently acquired L1 copies in the
genome, have very low sequence divergence from the L1 con-
sensus sequence and are polymorphic in the population (found
in some individuals but absent in others) [41]. If a cell type sup-
ports a high L1 retrotransposition rate, is this due to the activity
of a few hot donor L1s, or is it the result of L1 mRNAs being
widely expressed in line with concerted, genome-wide dys-
regulation? To address this question, Philippe et al. [105]
recently designed an assay that discriminated near-identical
donor L1s by mapping the 5’ and 3’ genome junction
sequences of all of the potentially active donor L1s in a set of
somatic cell lines and intersecting these data with transcrip-
tional and epigenetic signatures. The authors found that
donor L1s were generally inactive, with a limited number
active in each of the cell lines examined. These results
suggested cell-type-specific activity of retrotransposition-
competent L1s, presumably as only some L1s escaped silencing
in each cell type. However, a previous study [125] identified a
large number of L1s that were actively expressed in multiple
hESC lines, suggesting that patterns of donor L1 activation
may differ in pluripotent and differentiated cells, albeit with
a different approach in each study.
8.2. Retrotransposon silencing mechanisms
As retrotransposition events can cause such large effects on
gene expression, cell function and ultimately organism
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mobilization in germ and neural cells. These mechanisms
have been reviewed comprehensively [126,127]. We will
focus here on mechanisms thought to regulate retrotransposi-
tion during neural cell differentiation, a process that must be
tightly regulated during critical stages of brain development,
as differences have been observed in retrotransposition effi-
ciency between proliferating NPCs and postmitotic neurons
[12,76]. It is known that different DNA methylation patterns
are present across neurodevelopmental stages [128]. Presum-
ably, dynamic methylation during developmental processes,
such as neuronal differentiation, can offer windows of oppor-
tunity for retrotransposition to occur [76]. Additionally,
different neuronal subtypes (such as GABAergic inter-
neurons and glutamatergic projection neurons from the
prefrontal cortex (PFC)) are known to present differences in
their methylation patterns [129]. A recent study investigating
methylation of the L1 5’ UTR, which is a critical predictor of
L1 promotor activity [76,130], found no differences in the
levels of methyl-cytosine and 5-hydroxy-methyl-cytosine
across frontal cortex, hippocampus, cerebellum and basal
ganglia regions in the adult mouse brain [131]. Nevertheless,
subtle differences in L1 methylation state across neuronal
types and brain areas could potentially be missed when
analysing bulk tissue samples.
Several epigenetic factors are known to repress L1. For
example, methyl-CpG-binding protein 2 (MeCP2) is present
ubiquitously in the body and in higher abundance in
mature neurons. MeCP2 binds 5-methyl-cytosine residues
in CpG dinucleotides and interacts with histone deacetylase
protein (HDAC) and transcriptional SIN3A corepressor com-
plexes to repress transcription [132–134]. MeCP2 knockout
mice show an increase in L1 promoter activity consistent
with MeCP2 functioning as an L1 repressor [74,135]. Valproic
acid inhibition of HDAC1 enhances the transcriptional
activity of L1 [136], indicating that HDAC1 is also involved
in L1 repression. Another deacetylase suggested to inhibit
L1 is mono-ADP ribosyltransferase enzyme, or Sirtuin 6
(SIRT6), that was shown to localize to the L1 promoter
[137]. SIRT6 is expressed in neurons and appears to be dis-
placed in oxidative stress conditions and during ageing
[138]. Although L1 is repressed by these epigenetic mechan-
isms, the brain appears to exhibit lower L1 methylation
than found for other tissues, such as skin [76].
In addition to epigenetic regulation, retrotransposon
activity can be regulated by specific TFs, such as yin yang 1
(YY1), runt-related transcription factor 3 (RUNX3), SOX2
and tumour protein p53 (p53). YY1 is a zinc finger protein
expressed ubiquitously in the brain. It is critical for regional
patterning of the brain and neuronal differentiation, as it
regulates genes including Otx2 and Engrailed 2 [139–141].
YY1 positively regulates L1 by directing the RNA polymerase
II complex to its proper binding site [142,143]. RUNX3, which
is involved in neurogenesis, development and survival of
proprioceptive neurons, also positively regulates the L1 pro-
moter [144–146]. Conversely, the TF SOX2, involved in the
maintenance of the multi-potent state of neural stem cells
(NSCs), has been shown to inhibit L1 transcription
[72,73,76,147–149]. This is also the case for p53, a master reg-
ulator of cell cycling that is involved in neural proliferation
and differentiation (reviewed in [150]). p53 may suppress
L1 retrotransposition through its involvement in H3K9 tri-
methylation (H3K9me3), a silencing marker, at the L1 5’UTR [151,152]. As new L1 insertions carry TF binding sites
and potentially attract epigenetic suppression [153], the inte-
gration of an L1 into an intron or an intergenic region
immediately upstream of a protein-coding gene can alter
the expression pattern of that gene. L1 insertions are thought
to be particularly harmful if oriented in sense to the gene,
based on a depletion of these insertions from the human
population [99,154], and also the length of the insertion
may influence its impact [99]. Host factors, such as apolipo-
protein B mRNA editing enzyme catalytic subunit 3A
(APOBEC3A) [155], or DNA repair factors such as ATM
[54], can therefore counteract the impact of L1 at the insertion
site by limiting the length of L1 insertions [156]. Hence, even
if the host cell fails to prevent the integration of a new L1
copy, it may mitigate the potential consequences that
L1 insertion has upon the genome.
8.3. Environmental factors impacting retrotransposition
Numerous studies have proposed that environmental factors
may trigger hyperactivation of L1 and other retrotranspo-
sons. However, most of these studies are preliminary and
the experiments have been largely performed on cell lines.
For instance, heavy metals such as mercury, nickel and cad-
mium seem to increase L1 retrotransposition in HeLa and
neuroblastoma cells [157–159], and so does oxidative stress
[160]. Pollutants such as benzo[a]pyrene (BaP), a polycyclic
aromatic hydrocarbon ubiquitously found in grilled meats,
tobacco smoke, vehicle exhaust, domestic wood and coal
fires, have also been found to be involved in L1 retrotranspo-
sition [161]. Similarly, an L1-lacZ retrotransposition assay
showed that UV light and heat-shock induces an increase
in b-galactosidase activity in tumour cell lines [162]. The
increase in L1 activity as a result of environmental insults
may occur via an indirect pathway, for example, L1 retrotran-
sposon may leverage the DNA double-stranded breaks
induced by heavy metal toxicity to mobilize and insert at
new genomic locations. Indeed, Morrish et al. [163] described
an endonuclease-deficient engineered L1 that could readily
retrotranspose in cell lines lacking DNA repair mechanisms.
However, Farkash et al. [164] reported no increase in
retrotransposition of an endonuclease-deficient L1 after appli-
cation of gamma radiation, which is known to induce DNA
double-strand breaks. It therefore remains unclear whether
L1 can easily integrate, through an endonuclease-indepen-
dent mechanism, at preformed DNA double-strand breaks.
Alternatively, the cellular machinery could use L1 to induce
apoptosis or repair DNA damage through a compensatory
mechanism [161,163,165]. Although these environmental
insults are known to impact neurogenesis and brain function,
a link between these factors and an increase in retrotranspo-
sition in neurons or brain tissue has not been formally
demonstrated in vivo.9. Retrotransposition in neurological
disease
Retrotransposition in the early embryo and committed germ-
line can result in heritable mutations that cause genetic
disease [11,63]. Several retrotransposon insertions involved
in genetic neurologic diseases have been reported to date
(table 1). As stress-responsive elements, retrotransposons
Table 1. Studies associating retrotransposons with neurological disease. Here, we consider association as a study having shown that a retrotransposon insertion,
or insertions, may cause a disease, or the study having reported elevation of retrotransposon copy number or mRNA level in the brain tissue of affected
individuals when compared with healthy individuals.
retrotransposon
neurological disease
insertions activity (mRNA levels, CNV, biomarkers)
HERV multiple sclerosis [166–168]
3q13.31 microdeletion syndrome [169]
amyotrophic lateral sclerosis [170,171]
multiple sclerosis [166–168,172]
schizophrenia [173–176]
bipolar disorder [173,175,177]
HIV-associated dementia [178]
major depression [177]
autism [179]
ADHD [180]
L1 pyruvate dehydrogenase complex deﬁciency [110]
Fukuyama-type congenital muscular dystrophy [181]
neuroﬁbromatosis type I [182]
ataxia with oculomotor apraxia 2 [183]
glioblastoma [184,185]
schizophrenia [176]
ataxia telangiectasia [54]
Cofﬁn Lowry syndrome [186]
major depression [187,188]
schizophrenia [187–189]
Rett syndrome [74]
autism [190]
cocaine addiction [191]
post-traumatic stress disorder [192]
Alu autosomal dominant optic atrophy [193]
adrenoleukodystrophy [194]
neuroﬁbromatosis type I [182,195]
lipoprotein lipase deﬁciency [196]
spastic paraplegia [197,198]
Hunter disease [199]
Menkes disease [200]
Walker–Warburg syndrome [201]
Lesch–Nyhan disease [202]
glycogen storage disease type II [203]
post-traumatic stress disorder [192]
SVA neuroﬁbromatosis type I [204]
X-linked dystonia-parkinsonism [101–103,205]
Fukuyama muscular dystrophy [206]
n.a.
processed pseudogenes spinal muscular atrophy [207] n.a.
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and thereby generate somatic insertions with the potential
to influence neurological diseases of developmental and
degenerative origin. Early developmental stress factors, as
well as environmental insults occurring later in life, are
major risk factors for developing neuropsychiatric and neuro-
degenerative disorders [208]. Although many studies report
elevated retrotransposon copy numbers, mRNA levels or ret-
roviral markers in neurological diseases, to date there are
essentially no confirmed causative links established between
any neurological condition and somatic retrotransposition.
Here, we present an overview of the most relevant findings
in this area from L1 and Alu data. The implication of
HERVs in neurological disease, such as multiple sclerosis,
schizophrenia and bipolar disorder, has been recentlyreviewed [178,209,210]. The involvement of SVA retrotran-
sposons in neurological disease has also been recently
reviewed [211,212]. Processed pseudogenes in the context of
neuropathology have not been studied extensively, to our
knowledge.
9.1. Neurodevelopmental and psychiatric disease
A prominent example of a neurodevelopmental disorder that
has been linked to retrotransposon activity is Rett syndrome
(RTT). RTT is a progressive, severe neurodevelopmental dis-
ease associated with a mutation in the MeCP2 gene [213].
MeCP2 globally regulates methylated DNA and, as men-
tioned above, has been shown to repress L1 transcription
and retrotransposition [74,135]. Mice lacking functional
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number in brain [74]. Increased retrotransposition of the L1-
EGFP reporter has been observed in MeCP2 mutant rat
NSC cultures and transgenic mice [74]. Elevated L1 mRNA
abundance and L1-EGFP reporter activity were also found
in NPCs differentiated from induced pluripotent stem cells
(iPSCs) derived from RTT patient fibroblasts [74]. However,
it remains unclear whether susceptibility to increased L1 ret-
rotransposition in RTT patients can act as a driving force for
disease phenotype or progression, or is a peripheral outcome
of MeCP2 mutation.
Psychiatric diseases, such as autism, schizophrenia and
bipolar disorder, have also been linked with retrotransposon
activity [177,179,187,188,190–192]. The aetiology of these dis-
orders involves polygenic and environmental risk factors.
Recreational drugs that cause addiction, such as meth-
amphetamines (METH) and cocaine, are major risk factors
for the development of psychiatric disorders [214,215] and
have been reported to affect L1 retrotransposition in cell
lines and rodent brains [216,217]. One study reported elev-
ated L1 mRNA and ORF2p levels after METH exposure in
rat neurogenic areas [217]. Both METH and cocaine can
induce L1 retrotransposition in cultured neuroblastoma cell
lines, as determined by L1-EGFP [217] and L1-neomycin
reporter assays [216]. In cell culture, METH and cocaine do
not induce DNA breaks, as revealed by the absence of
gamma H2A histone family X (H2AX) phosphorylation at
serine 139, a marker for double-strand DNA breaks [216].
Instead, L1 mobilization in response to METH and cocaine
treatment may occur via the cyclic AMP response element-
binding protein pathway mediating ORF1p access to chroma-
tin [216]. In a recent study, Doyle et al. [191] sought to further
test the potential link between L1 insertions and cocaine in
brain tissue of cocaine addicts and controls. The authors
employed a TaqMan ddPCR assay and found no significant
increase in the L1 mRNA transcript levels in the cocaine
group [191]. WGS performed on pools of neuronal and
non-neuronal nuclei, as well as blood samples from cases
and controls, revealed no significant increase in the number
of L1 insertions in cocaine samples compared with controls
[191]. The authors reported gene ontology terms, potentially
important for cocaine signalling pathways, to be enriched for
genes harbouring L1 insertions found in the cocaine group
and not observed in the control. However, the study had sev-
eral caveats which could be addressed in future research.
Samples were pooled across control or case individuals, rely-
ing on a ddPCR assay to determine the allele frequency of
insertions in each individual. Furthermore, insertions were
detected based only on the 3’ end of L1 and 100 nt single-
end Illumina reads, and therefore were not fully resolved
and characterized. How and whether these new insertions
ultimately contribute to addiction is still very much unclear.
The relevant studies have to date not incorporated single-
cell genomic analysis with full characterization of candidate
somatic insertions.
Increased retrotransposon copy number and mRNA
levels have been reported in schizophrenia and depression
[187,192]. Bundo et al. [187] revealed a significant increase
in L1 ORF2 copy number in neurons isolated from schizo-
phrenia PFC when compared with matched control
neurons. This result was replicated in iPSC-derived neurons
from patients affected by 22q11 deletion, a mutation found
in a number of schizophrenia patients and considered ahigh genetic risk factor [218]. A consistent increase in L1
copy number was also observed in the PFC tissue of two
established schizophrenia animal models (i.e. maternal
immune activation induced by polyinosinic : polycytidylic
acid (PolyI : C) and epidermal growth factor (EGF)) [187].
WGS performed on neuronal nuclei and liver samples
revealed no increase in L1 insertion number in patients
when compared with controls. The authors reported that
the L1 insertions in schizophrenia patients were more fre-
quently present in genes important for synaptic function
and schizophrenia-related genes [187]. However, the inser-
tions were not validated and characterized. Moreover,
many of the brain-specific insertions appeared from inactive,
old L1 subfamilies, which could not have accounted for de
novo retrotransposition. Another study reported significant
L1 promotor hypomethylation in the PolyI : C model of
maternal immune activation, which could explain elevated
L1 transcription [219]. Very recently, Bedrosian et al. [79] pro-
posed that low maternal care, another risk factor for
schizophrenia and other psychiatric disorders, may elevate
L1 retrotransposition in the hippocampus. This study,
based largely on a qPCR L1 CNV assay, estimated higher
L1 copy number and transcript levels in mice after low
maternal care when compared with those reared in high
maternal care conditions. The authors reported no change
in neurogenesis between the two groups. However, the elev-
ated L1 transcript levels correlated with hypomethylation of
L1 at a YY1 TF binding site [79]. As a qPCR assay cannot
prove L1 integration, it remains unclear whether the differ-
ence in L1 copy number and transcript abundance was
reflected by an increase in retrotransposition. Consistent L1
upregulation across various schizophrenia experimental
systems indicates a strong association between disease
phenotype and L1 activity, although it remains unclear
whether L1 is a driver or a passenger with respect to
neuropathology and, again, single-cell genomic analyses sup-
porting elevated L1 mobilization, as opposed to L1 CNV,
have yet to be published.
Even if elevated somatic retrotransposition ultimately is
not found to occur in a given neurological condition, a mol-
ecular signature of L1 regulatory disruption may indicate a
wider landscape of epigenome abnormality, and prove
useful as a diagnostic tool. For example, altered L1 and
Alu epigenetic regulation has been reported in post-
traumatic stress disorder (PTSD), an anxiety condition
characterized by persistent re-experiences of a past trau-
matic event or events [192]. PTSD patients within a cohort
of military personnel assessed post-deployment showed
hypermethylation of L1 and Alu in serum when compared
with healthy individuals [192]. Non-PTSD post-deployment
individuals also exhibited a hypermethylation pattern when
compared with the same individuals pre-deployment. These
two observations are intriguing and might suggest an adap-
tive stress response mediated by retrotransposon repression
or pre-existing methylation in PTSD cases compared with
controls [220]. These findings could be buttressed by
experiments performed using animal models where L1
methylation and CNV could be analysed in brain tissue.
Overall, a theme has emerged of L1 activation in a wide
range of neurological disorders. More research is required
in this area to understand whether there is a functional con-
sequence of L1 mobilization in schizophrenia and other
psychiatric disorders.
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Neurodegenerative conditions, such as Parkinson’s disease,
Huntington’s disease and Alzheimer’s disease, represent a
group of nervous system disorders characterized by the selec-
tive death of neuronal subsets in particular brain regions
[221]. Experimental data showing somatic retrotransposition,
or even the broad involvement of retrotransposons, in neuro-
degeneration are quite scarce. To speculate, dysfunctional
epigenetic silencing, deficient DNA repair and oxidative
stress could all lead to retrotransposon activation associated
with neuronal degeneration or to the progression of degen-
erative processes. As an instructive example, L1 copy
number was found via a qPCR-based assay to be elevated
in hippocampal neurons from ataxia telangiectasia patients
[54]. These patients presented a loss of function mutation in
the ATM gene encoding a serine/threonine kinase [222],
which leads to neuronal degeneration [223]. ATM responds
to double-stranded DNA breaks by phosphorylating down-
stream factors and activating DNA damage checkpoints,
thus leading to cell cycle arrest and to the repair of damaged
DNA or p53-mediated apoptosis [223]. ATM mutation in cul-
tured human NPCs and ATM knockout in L1-EGFP mice
significantly increased L1-EGFP retrotransposition, measured
by the number of GFP-positive cells, without affecting L1
promoter activity or endogenous ORF1p levels, and with
no change in cell division rates or survival [54]. Notably,
longer L1 insertions appeared to occur in ATM mutant cells
[54], potentially owing to the role of ATM in cellular DNA
repair, which may interfere with host defences against L1 ret-
rotransposition under wild-type conditions. Further analysis,
preferably in vivo, is required to corroborate these results, and
identify the role of ATM in controlling L1 integration.
As many neurodegenerative conditions are associated
with ageing, retrotransposition in neurodegenerative con-
ditions may, in general, reflect conditions encountered in
senescent cells. Accumulation of oxidative DNA damage
and unrepaired DNA, as well as changes in methylation pat-
terns commonly associated with ageing, might lead to
reduced silencing of retrotransposition in the brain. As an
example of this, TAR DNA-binding protein 43 (TDP-43) is a
nucleic acid binding protein involved in transcriptional
repression and RNA metabolism during stress response.
Mutant TDP-43 is usually associated with neurodegenerative
disorders, but it can also be present in healthy elderly people
[224]. Accumulation of TDP-43 in tau-negative and ubiquitin-
positive cytoplasmic inclusions is a neuropathological
hallmark in neurodegenerative conditions, such as amyotrophic
lateral sclerosis (ALS) and frontotemporal lobar dementia
(FTLD) [225]. Transcriptomic analyses performed on brain
tissue obtained from TDP-43 mutant mice and mice expres-
sing human mutant TDP-43 showed an overall increase in
retrotransposon expression [226]. Moreover, surveys of
protein–RNA interactions and gene expression performed
on FTLD brain samples versus matched controls found a sig-
nificantly reduced association of mutant TDP-43 at its target
retrotransposons in patients [226]. Another recent study,
wherein human TDP-43 was expressed in Drosophila brains,
recapitulated these results from patients and mouse models,
demonstrating thatTDP-43dysfunction results inde-repression
of retrotransposons [227]. Interestingly, the expression of
human TDP-43 specifically in fly glial cells led to an early
and significant increase in gypsy ERV transcript levels aspreviously reported to be elevated in ageing flies [228].
Human TDP-43 in the fly glia resulted in a high number of
apoptotic nuclei, very significant motor impairment and
shortened lifespan. Knockdown of gypsy ameliorated this
phenotype, suggesting that gypsy may be involved in cell
death, potentially by mediating DNA damage [227].
Many neurodegenerative disorders are strongly linked
with mitochondrial dysfunction. In intriguing recent work,
Larsen et al. [229] put forward the hypothesis that retrotran-
sposons were involved in mitochondrial gene dysfunction
observed in neurodegeneration. Analysis of the retrotranspo-
son sequence content in over a thousand mitochondrial
genes, in conjunction with randomly selected protein-
coding genes, showed an enrichment for Alu within and
adjacent to mitochondrial genes [229]. Previous studies
have identified L1 and Alu retrotransposon insertions in a
number of translocase of outer mitochondrial membrane
genes [4,230,231]. Moreover, Alu insertions in two genes
involved in mitochondria stabilization and function led to
disorders with a neurodegenerative component [193,194].
More studies, in cell culture and animal models, are required
to test if Alu activity can preferentially insert into and induce
mitochondrial gene disruption.10. Concluding remarks
It is now well established that retrotransposon-driven mosai-
cism can occur in the mammalian brain. Dynamism in TF
activity, and that of other regulatory mechanisms described
to act during embryonic and adult neurogenesis, provides a
temporal and spatial niche amenable to retrotransposition.
Additionally, retrotransposition may not be limited to
NPCs; it may also take place in postmitotic neurons. Further
proof is required to be certain that this can occur in vivo, and
the regulatory mechanisms involved in allowing L1 retrotran-
sposition in mature neurons require further investigation.
Environmental stress, as well as genetic dysfunction in L1
silencing factors, can result in high retrotransposition levels,
and possibly lead to neurological disease. This also requires
extensive investigation, as we lack even basic understanding
of the pathways on which stress factors or dysfunction
in silencing factors can act to impact retrotransposition in
neural cells. Our understanding of retrotransposition in the
brain is still very much in its infancy.
Further advances in single-cell genomics (and perhaps
taking Eric Kandel’s reductionist approach of ‘one cell at a
time’ to focus on very well-defined neuronal subtypes
[232]) to understand the precise timing of retrotransposition,
and its regulation, are required at this point, and will also
advance our knowledge of which neuronal types and
contexts best support endogenous L1 retrotransposition.
Genome-editing tools, such as the CRISPR–Cas9 system
[233], may be employed in the near future to resolve L1
insertions identified in patient samples and introduce
these faithfully into neuronal cultures or animal models, to
evaluate their impact on gene expression and, potentially,
neurobiological phenotype. This approach may prove to be
a viable alternative to the current transgenic approaches
used to study engineered L1 mobilization in the brain, and
would bring us closer to understanding whether endogenous
retrotransposition has an impact upon neurobiology and
neurological disease.
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